Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

Tango has dosed the first subject in the Phase I/II trial of TNG462 with Revolution Medicines' daraxonrasib or zoldonrasib.

BioAtla has presented first-in-human Phase I study data of its anticancer therapy, BA3182, targeting those with metastatic adenocarcinoma.

The trial readout comes at a time of turbulence in the vaccine sector after RFK Jr replaced every member of the ACIP panel.

The China NMPA's CDE has granted approval to the IND application of InnoCare Pharma to initiate the trial of ICP-B794.

Novartis’ Cosentyx (secukinumab) has failed to show any benefit in the Phase III study in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the GCAptAIN trial (NCT04930094), ...

Cidara Therapeutics has reported encouraging top-line outcomes from the Phase IIb NAVIGATE trial of the investigational ...

Bio-Thera Solutions has commenced dosing in the randomised Phase III trial of the antibody-drug conjugate (ADC) BAT8006.

Neuron23 has dosed the first subject in the global Phase II NEULARK trial of NEU-411 for early Parkinson's disease (PD).